Skip to main content

Advertisement

SpringerLink
Log in

HIV Infections: The Global Epidemiology and Goals for Vaccine Research

  • Review Article
  • Published:
Molecular Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. (1998) Monitoring the AIDS pandemic (MAP). The status and trends of the HIV/AIDS epidemics in the world. Geneva MAP, pp. 1–27.

  2. Nicoll A, Gill ON. (1999) The global impact of HIV infection and disease. Commun. Dis. Public Health 2: 85–89.

    PubMed  CAS  Google Scholar 

  3. Joint United Nations Programme on AIDS (UNAIDS) and the World Health Organization (WHO). Report on the global HIV/AIDS epidemic June 1998. UNAIDS & WHO, Geneva, pp. 1–58.

  4. Stoneburner R, Low-Beer D, Tembo G, Mertens T, Asiimus-Okiror G. (1996) Human immunodeficiency virus dynamics in East Africa deduced from surveillance data. Am. J. Epidemiol. 144: 682–695.

    Article  PubMed  CAS  Google Scholar 

  5. Tarantola D, Schwartlander B. (1997) HIV/AIDS epidemics in sub-Saharan Africa: dynamism, diversity and discrete declines? AIDS 11 (suppl B): S5–S21.

    PubMed  Google Scholar 

  6. Fylkesnes K, Musonda RM, Kasumba K, et al. (1997) The HIV epidemic in Zambia: socio-demographic prevalence patterns and indications of trends among childbearing women: AIDS 11: 339–45.

    Article  PubMed  CAS  Google Scholar 

  7. Hu DJ, Dondero TJ, Rayfield MA, et al. (1996) The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. JAMA 275: 210–216.

    Article  PubMed  CAS  Google Scholar 

  8. Hu DJ, Buvé A, Baggs J, van der Groen G, Dondero TJ. (1999) What role does HIV-1 subtype play in trasmission and pathogenesis? An epidemiological perspective. AIDS 13: 873–881.

    Article  PubMed  CAS  Google Scholar 

  9. Dolin R, Masur H, Saag MS (eds.) (1999) AIDS Therapy. Churchill Livingstone, Philadelphia.

    Google Scholar 

  10. CDSC/PHLS: Changes in the incidence of AIDS and in AIDS deaths: the effects of anti-retroviral treatment. CDR Wkly 1997 7: 381.

  11. Mouton Y, Alfandari S, Valette M, et al. (1997) Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1: F101–F105.

    Article  Google Scholar 

  12. Centers for Disease Control and Prevention. (1997) Update: trends in AIDS incidence, deaths, and prevalence-United States, 1996. MMWR 46: 165–173.

    Google Scholar 

  13. Hogg RS, O’Shaughnessy MV, Gataric N, et al. (1997) Decline in deaths from AIDS due to new antiretrovirals (letter). Lancet 349: 1294.

    Article  PubMed  CAS  Google Scholar 

  14. Pezzotti P, Napoli PA, Acciai S, et al. (1999) Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. AIDS 13: 249–255.

    Article  PubMed  CAS  Google Scholar 

  15. Delta Coordinating Committee. (1996) Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348: 283–291.

    Article  Google Scholar 

  16. Cameron DW, Heath-Chiozzi M, Kravcik S, Mills R, Potthoff A, Henry D. (1996) Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: update. XI International Conference on AIDS. Vancouver, July 1996 vol 1: 24 [abstract MoB411].

  17. Hammer SM, Squires KE, Hughes MD, et al. (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337: 725–733.

    Article  PubMed  CAS  Google Scholar 

  18. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. (1997) Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 11: 1731–1738.

    Article  PubMed  CAS  Google Scholar 

  19. Hirschel B, Francioli P. (1998) Progress and problems in the fight against AIDS. N. Engl. J. Med. 338: 906–908.

    Article  PubMed  CAS  Google Scholar 

  20. Connor EM, Sperling RS, Gelber R, et al. (1994) Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N. Engl. J. Med. 331: 1173–1180.

    Article  PubMed  CAS  Google Scholar 

  21. Seage GR, Mayer KH, Horsburgh CR. (1993) Risk of human immunodeficiency virus infection from unprotected receptive anal intercourse increases with decline in immunologic status of infected partners. Am. J. Epidemiol. 137: 899–908.

    Article  PubMed  Google Scholar 

  22. Lee TH, Sakahara N, Fiebig E, Busch MP, O Brien TR, Herman SA. (1996) Correlation of HIV-1 RNA levels in plasma and heterosexual transmission of HIV-1 from infected transfusion recipients. J. Acquir. Immune Defic. Syndr. Hum. Retrov. 12: 427–428.

    Article  CAS  Google Scholar 

  23. Ragni MV, Faruki H, Kingsley LA. (1998) Heterosexual HIV-1 transmission and viral load in hemophilic patients. J. Acquir. Immune Defic. Syndr. Hum. Retrov. 17: 42–45.

    Article  CAS  Google Scholar 

  24. Vernazza PL, Eron JJ, Fiscus SA, Cohen MS. (1999) Sexual transmission of HIV: infectiousness and prevention. AIDS 13: 155–166.

    Article  PubMed  CAS  Google Scholar 

  25. Zhu T, Zang N, Carr A, et al. (1996) Generic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J. Virol. 70: 3098–4107.

    PubMed  PubMed Central  CAS  Google Scholar 

  26. Coombs RW, Speck CE, Hughes JP, et al. (1998) Association between culturable human immunodeficiency virus type 1(HIV-1) in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J. Infect. Dis. 177: 320–330.

    Article  PubMed  CAS  Google Scholar 

  27. Cohen MS, Hoffman IF, Royce RA, et al. (1997) Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 349: 1868–1873.

    Article  PubMed  CAS  Google Scholar 

  28. Mostad SB, Overbaugh J, DeVange DM, et al. (1997) Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 350: 922–927.

    Article  PubMed  CAS  Google Scholar 

  29. Zhang H, Dornadula G, Beumont M, et al. (1998) Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N. Engl. J. Med. 339: 1803–1809.

    Article  PubMed  CAS  Google Scholar 

  30. Mayaux MJ, Teglas JP, Mandelbrot L, Berebi A, Gallais H, Matherton S. (1997) Acceptability and impact of zidovudine prevention on mother-to-child HIV 1 transmission in France. J. Paediatr. 131: 857–862.

    Article  CAS  Google Scholar 

  31. Fiscus SA, Adimora AA, Schoenbach VJ, et al. (1996) Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA 275: 1483–1488.

    Article  PubMed  CAS  Google Scholar 

  32. Stringer JSA, Rouse DJ, Goldenberg RL. (1999) Prophylactic cesarean delivery for the prevention of perinatal human immunodeficiency virus transmission: the case for restraint. JAMA 281: 1946–1949.

    Article  PubMed  CAS  Google Scholar 

  33. The International Perinatal HIV Group. (1999) The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N. Engl. J. Med. 340: 977–987.

    Article  Google Scholar 

  34. The European Mode of Delivery Collaboration. (1999) Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 353: 1035–1039.

    Article  Google Scholar 

  35. Shaffer N, Chuachoowong R, Mock PA, et al. (1999) Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 353: 773–780.

    Article  PubMed  CAS  Google Scholar 

  36. Wiktor SZ, Ekpini E, Karon JM, et al. (1999) Short course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d’Ivoire: a randomised trial. Lancet 353: 781–785.

    Article  PubMed  CAS  Google Scholar 

  37. Dabis F, Msellati P, Meda N, et al. (1999) 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovidine to reduce vertical transmission of HIV in breasted children in Côte d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 353: 786–792.

    Article  PubMed  CAS  Google Scholar 

  38. Mansergh G, Haddix AC, Steketee RW, et al. (1996) Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan Africa developing country setting. JAMA 276: 139–145.

    Article  PubMed  CAS  Google Scholar 

  39. Söderlund N, Zwi K, Kinghorn A, Gray G. (1999) Prevention of vertical transmission of HIV: analysis of cost effectiveness of options available in South Africa. BMJ 318: 1650–1656.

    Article  PubMed  PubMed Central  Google Scholar 

  40. (1998) AIDS, the unbridgable gap. Lancet 351: 1825.

  41. Guay LA, Musoke P, Fleming T, et al. (1999) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 354: 795–802.

    Article  PubMed  CAS  Google Scholar 

  42. Forsythe S, Gilks C. (1999) Economic issues and antiretroviral therapy in developing countries. Trans. R. Soc. Trop. Med. Hyg. 93: 1–3.

    Article  PubMed  CAS  Google Scholar 

  43. Langlois AJ, Desrosiers RC, Lewis MG, et al. (1998) Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus. J. Virol. 72: 6950–6955.

    PubMed  PubMed Central  CAS  Google Scholar 

  44. Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, Koup RA. (1997) Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med. 3: 1389–1393.

    Article  PubMed  CAS  Google Scholar 

  45. Prince AM, Reesink H, Pascual D, et al. (1991) Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res. Hum. Retro. 7: 971–973.

    Article  CAS  Google Scholar 

  46. Emini EA, Schleif WA, Nunberg JH, et al. (1992) Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355: 728–730.

    Article  PubMed  CAS  Google Scholar 

  47. Mascola JR, Snyder SW, Weislow OS, et al. (1996) Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173: 340–348.

    Article  PubMed  CAS  Google Scholar 

  48. Belshe RB, Graham BS, Keefer MC, et al. (1994) Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 272: 475–480.

    Article  PubMed  CAS  Google Scholar 

  49. Belshe RB, Gorse GJ, Mulligan MJ, et al. (1998) Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 12: 2407–2415.

    Article  PubMed  CAS  Google Scholar 

  50. Belshe RB, Bolognesi DP, Clements ML, et al. (1994) HIV infection in vaccinated volunteers. JAMA 272: 431.

    Article  PubMed  CAS  Google Scholar 

  51. Kahn JO, Steimer KS, Baenziger J, et al. (1995) Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial. J. Infect. Dis. 171: 1343–1347.

    Article  PubMed  CAS  Google Scholar 

  52. Reitter JN, Means RE, Desrosiers RC. (1998) A role for carbohydrates in immune evasion in AIDS. Nat. Med. 4: 679–684.

    Article  PubMed  CAS  Google Scholar 

  53. Devico A, Silver A, Thronton AM, Sarngadharan MG, Pal R. (1996) Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates. Virology 218: 258–263.

    Article  PubMed  CAS  Google Scholar 

  54. LaCasse RA, Follis KE, Trahey M, Scarborough JD, Littman DR, Nunberg JH. (1999) Fusioncompetent vaccines: broad neutralization of primary isolates of HIV. Science 283: 357–362.

    Article  PubMed  CAS  Google Scholar 

  55. Koup R. A., Safrit J. T., Cao Y., et al. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68: 4650–4655.

    PubMed  PubMed Central  CAS  Google Scholar 

  56. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MBA. (1994) Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68: 6103–6110.

    PubMed  PubMed Central  CAS  Google Scholar 

  57. Yasutomi Y, Reimann KA, Lord CI, Miller MD, Letvin NL. (1993) Simian immunodeficiency virus-specific CD8+ T lymphocyte response in acutely infected rhesus monkeys. J. Virol. 67: 1707–1711.

    PubMed  PubMed Central  CAS  Google Scholar 

  58. Kuroda MJ, Schmitz JE, Charini WA, et al. (1999) Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J. Immunol. 162: 5127–5133.

    PubMed  CAS  Google Scholar 

  59. Schmitz JE, Kuroda MJ, Santra S, et al. (1999) Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283: 857–860.

    Article  PubMed  CAS  Google Scholar 

  60. Price DA, Goulder PJ, Klenerman P, et al. (1997) Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl. Acad. Sci. U.S.A. 94: 1890–1895.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Goulder PJ, Phillips RE, Colbert RA, et al. (1997) Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3: 212–217.

    Article  PubMed  CAS  Google Scholar 

  62. Borrow P, Lewicki H, Wei X, et al. (1997) Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3: 205–211.

    Article  PubMed  CAS  Google Scholar 

  63. Wilson CC, Brown RC, Korber BT, et al. (1999) Frequent detection of escape from cytotoxic T-lymphocyte recognition in perinatal human immunodeficiency virus (HIV) type 1 transmission: the ariel project for the prevention of transmission of HIV from mother to infant. J. Virol. 73: 3975–3985.

    PubMed  PubMed Central  CAS  Google Scholar 

  64. Wagner R, Leschonsky B, Harrer E, et al. (1999) Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term nonprogressor: constraints on immune escape associated with targeting a sequence essential for viral replication. J. Immunol. 162: 3727–3734.

    PubMed  CAS  Google Scholar 

  65. Ferrari G, Humphrey W, McElrath MJ, et al. (1997) Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc. Natl. Acad. Sci. U.S.A. 94: 1396–1401.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  66. Cao H, Kanki P, Sankale JL, et al. (1997) Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development. J. Virol. 71: 8615–8623.

    PubMed  PubMed Central  CAS  Google Scholar 

  67. Rosenberg ES, Billingsley JM, Caliendo AM, et al. (1997) Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278: 1447–1450.

    Article  PubMed  CAS  Google Scholar 

  68. Schrum S, Probst P, Fleischer B, Zipfel PF. (1996) Synthesis of the CC-chemokines MIP-1α, MIP-1β, and RANTES is associated with a type 1 immune response. J. Immunol. 157: 3598–3604.

    PubMed  CAS  Google Scholar 

  69. Miskovsky E. P., Liu A. Y., Pavlat W., et al. (1994) Studies of the mechanism of cytolysis by HIV-1-specific CD4+ human CTL clones induced by candidate AIDS vaccines. J. Immunol. 153: 2787–2799.

    PubMed  CAS  Google Scholar 

  70. Paul WE, Seder RA. (1994) Lymphocyte responses and cytokines. Cell 76: 241–251.

    Article  PubMed  CAS  Google Scholar 

  71. Rissoan MC., Soumelis V., Kadowaki N., et al. (1999) Reciprocal control of T helper cell and dendritic cell differentiation. Science 283: 1183–1186.

    Article  PubMed  CAS  Google Scholar 

  72. Doherty TM, Coffman RL. (1996) Leishmania major: effect of infectious dose on T cell subset development in BALB/c mice. Exp. Parasitol. 84: 124–135.

    Article  PubMed  CAS  Google Scholar 

  73. Sieling PA, Wang XH, Gately MK, et al. (1994) IL-12 regulates T helper type 1 cytokine responses in human infectious disease. J. Immunol. 153: 3639–3647.

    PubMed  CAS  Google Scholar 

  74. Cohen J. (1993) T cell shift: key to AIDS therapy? Science 262: 175–176.

    Article  PubMed  CAS  Google Scholar 

  75. Mestecky J, McGhee JR. (1987) Immunoglobulin IgA: molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv. Immunol. 40: 153–245.

    Article  PubMed  CAS  Google Scholar 

  76. Kraehenbuhl, JP, Neutra MR. (1992) Molecular and cellular basis of immune protection of mucosal surfaces. Physiological Rev. 72: 853–879.

    Article  CAS  Google Scholar 

  77. Kawabata S, Miller CJ, Lehner T, et al. (1998) Induction of Th2 cytokine expression for p27-specific IgA B cell responses after targeted lymph node immunization with simian immunodeficiency virus antigens in rhesus macaques. J. Infect. Dis. 177: 26–33.

    Article  PubMed  CAS  Google Scholar 

  78. McGhee JR, Kiyono H, Kubota M, et al. (1999) Mucosal Th1-versus Th2-type responses for antibody- or cell-mediated immunity to simian immunodeficiency virus in rhesus macaques. J. Infect. Dis. 179 (Suppl 3): S480–S484.

    Article  PubMed  CAS  Google Scholar 

  79. Petitprez K, Khalife J, Cetre C, et al. (1999) Cytokine mRNA expression in lymphoid organs associated with the expression of IgA response in the rat. Scand. J. Immunol. 49: 14–20.

    Article  PubMed  CAS  Google Scholar 

  80. Yamamoto S, Kiyono H, Yamamoto M, et al. (1997) A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. U.S.A. 94: 5267–5272.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  81. Whitmire JK, Asano MS, Murali-Krishna K, Suresh M, Ahmed R. (1998) Long-term CD4 Th1 and Th2 memory following acute lymphocytic choriomeningitis virus infection. J. Virol. 72: 8281–8288.

    PubMed  PubMed Central  CAS  Google Scholar 

  82. Poccia F, Battistini L, Cipriani B, et al. (1999) Phosphoantigen-reactive Vγ9Vδ2 T lymphocytes suppress in vitro human immunodeficiency virus type 1 replication by cell-released antiviral factors including CC chemokines. J. Infect. Dis. 180: 858–861.

    Article  PubMed  CAS  Google Scholar 

  83. Wallace M, Bartz SR, Chang W-L, MacKenzie D, Pauza CD, Malkovsky M. (1996) γδ T lymphocytes responses to human immunodeficiency virus. Clin. Exp. Immunol. 103: 177–184.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  84. Poccia F, Malkovsky M, Pollak A, et al. (1999) In vivo γδ T-cell priming to mycobacterial antigens by primary M. tuberculosis infection and exposure to nonpeptidic ligands. Mol. Med. 5: 471–476.

    PubMed  PubMed Central  CAS  Google Scholar 

  85. Jacob J, Baltimore D. (1999) Modeling T-cell memory by genetic marking of memory T cells in vivo. Nature 399: 593–597.

    Article  PubMed  CAS  Google Scholar 

  86. Sourdive DJ, Murali-Krishna K, Altman JD, et al. (1998) Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection. J. Exp. Med. 188: 71–82.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  87. Castan J, Tenner R, Racz P, Fleischer B, Broker BM. (1997) Accumulation of CTLA-4-expressing T lymphocytes in the germinal centres of human lymphoid tissues. Immunology 90: 265–271.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  88. Re MC, Furlini G, Vignoli M, et al. (1995) Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10: 408–416.

    Article  PubMed  CAS  Google Scholar 

  89. Zagury JF, Sill A, Blattner W, et al. (1998) Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J. Hum. Virol. 1: 282–292.

    PubMed  CAS  Google Scholar 

  90. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648–659.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  91. D’Souza MP, Harden VA. (1996) Chemokines and HIV-1 second receptors. Confluence of two fields generates optimism in AIDS research. Nat. Med. 2: 1293–1300.

    Article  PubMed  Google Scholar 

  92. Lynch JA, deSouza M, Robb MD, et al. (1998) Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais. J. Infect. Dis. 178: 1040–1046.

    Article  PubMed  CAS  Google Scholar 

  93. Bernard NF, Pederson K, Chung F, Ouellet L, Wainberg MA, Tsoukas CM. (1998) HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons. AIDS 12: 2125–2139.

    Article  PubMed  CAS  Google Scholar 

  94. Chenciner N, Michel F, Dadaglio G, et al. (1989) Multiple subsets of HIV-specific cytotoxic T lymphocytes in humans and in mice. Eur. J. Immunol. 19: 1537–1544.

    Article  PubMed  CAS  Google Scholar 

  95. Larsson M., Jin X., Ramratnam B., et al. (1999) A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS 13: 767–777.

    Article  PubMed  CAS  Google Scholar 

  96. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. (1998) HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391: 397–401.

    Article  PubMed  CAS  Google Scholar 

  97. Sette A, Sidney J. (1998) HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr. Opin. Immunol. 10: 478–482.

    Article  PubMed  CAS  Google Scholar 

  98. Thomson SA, Sherritt MA, Medveczky J, et al. (1998) Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J. Immunol. 160: 1717–1723.

    PubMed  CAS  Google Scholar 

  99. Woodberry T, Gardner J, Mateo L, et al. (1999) Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes. J. Virol. 73: 5320–5325.

    PubMed  PubMed Central  CAS  Google Scholar 

  100. Stott EJ, Chan WL, Mills KH, et al. (1990) Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet 336: 1538–1541.

    Article  PubMed  CAS  Google Scholar 

  101. Cranage MP, Polyanskaya N, McBride B, et al. (1993) Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res. Hum. Retroviruses 9: 13–22.

    Article  PubMed  CAS  Google Scholar 

  102. Arthur LO, Bess JW Jr, Urban RG, et al. (1995) Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J. Virol. 69: 3117–3124.

    PubMed  PubMed Central  CAS  Google Scholar 

  103. Polyanskaya N, Sharpe S, Cook N, et al. (1997) Anti-major histocompatibility complex antibody responses to simian B cells do not protect macaques against SIVmac infection. AIDS Res. Hum. Retroviruses 13: 923–931.

    Article  PubMed  CAS  Google Scholar 

  104. Cairns JS, Sarver N. (1998) New viral vectors for HIV vaccine delivery. AIDS Res. Hum. Retroviruses 14: 1501–1508.

    Article  PubMed  CAS  Google Scholar 

  105. Stott EJ, Schild GC. (1996) Strategies for AIDS vaccines. J. Antimicrob. Chemother. 37 (Suppl B): 185–98.

    Article  PubMed  CAS  Google Scholar 

  106. Vogel FR. (1998) Adjuvants in perspective. Dev. Biol. Stand. 92: 241–248.

    PubMed  CAS  Google Scholar 

  107. Alving CR, Detrick B, Richards RL, Lewis MG, Shafferman A, Eddy GA. (1993) Novel adjuvant strategies for experimental malaria and AIDS vaccines. Ann. N.Y. Acad. Sci. 690: 265–275.

    Article  PubMed  CAS  Google Scholar 

  108. Hoff R, Barker LF. (1995) Trial objectives and end points for measuring the efficacy of HIV vaccines. Infect. Agents Dis. 4: 95–101.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Drs. Carl Dieffenbach, Nava Sarver, and Paolo Miotti for helpful comments on the manuscript. This work was supported by Min-istero della Sanità, Ricerca corrente IRCCS Spallanzani and the NIH.

Author information

Authors and Affiliations

  1. Servizio di Epidemiologia delle Malattie Infettive IRCCS Ospedale Lazzaro Spallanzani, Centro di Riferimento AIDS, Rome, Italy

    Giuseppe Ippolito & Enrico Girardi

  2. Centro Operativo AIDS, Istituto Superiore di Sanità, Rome, Italy

    Giovanni Rezza

  3. Department of Medical Microbiology and Immunology, University of Wisconsin Medical School, 1300 University Avenue, Madison, Wisconsin, 53706, USA

    Miroslav Malkovsky

  4. Targeted Interventions Branch, Division of AIDS, NIAID, Bethesda, Maryland, USA

    J. Scott Cairns

Authors
  1. Giuseppe Ippolito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanni Rezza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Enrico Girardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miroslav Malkovsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Scott Cairns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Miroslav Malkovsky.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ippolito, G., Rezza, G., Girardi, E. et al. HIV Infections: The Global Epidemiology and Goals for Vaccine Research. Mol Med 6, 69–85 (2000). https://doi.org/10.1007/BF03401775

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03401775

Keywords

Search

Navigation